Back to search

Article

An in situ generated CAR-M with IFN-γ and negative dominance Sirpα isoform augments hepatocellular carcinoma immunotherapy

2025-12-11

Abstract excerpt

<h4>Background and Aims</h4> Chimeric antigen receptor (CAR) T cells have shown strong efficacy in hematological cancers but limited success in solid tumors. Macrophages, with their natural ability to infiltrate tumors, modulate immunity, and phagocytose cancer cells, offer a promising alternative when engineered with CARs. While studies have demonstrated the feasibility and anti-tumor activity of CAR macrophages...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2bc361cf-d42c-55c1-b1a3-260fc36a4ff0
DOI
10.64898/2025.12.08.693087
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
An in situ generated CAR-M with IFN-γ and negative dominance Sirpα isoform augments hepatocellular carcinoma immunotherapyDOI 10.64898/2025.12.08.693087
PD-L1 blockade restores CAR T cell activity through IFNγ-regulation of CD163+ macrophagesSemantic proximity
Cd73-LNPs promotes antitumor T-cell immunity via amplifying Tlr3-mediated immunostimulatory dendritic cell activationSemantic proximity
Organoid modeling of tumor-associated macrophages reveals phagocytosis checkpoint blockade-induced conversion to an immunosuppressive SPP1+ phenotypeSemantic proximity
Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorSemantic proximity
CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentationSemantic proximity
Breaking the immunosuppressive barrier: an armored CAR-M biotechnology with the original M1 phenotype dominance rescues antitumor immunity.Semantic proximity
Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.Semantic proximity
Development of a novel HER2-CAR monocyte cell therapy with controllable proliferation and enhanced anti-tumor efficacySemantic proximity
Multi-compartment immune and tumor cell reprogramming by IFNα2 overcomes colon cancer immunotherapy resistanceSemantic proximity
An anti-cancer cell therapy platform utilizing ex vivo physiologic dendritic cells expressing mRNA-encoded antigens and immune checkpoint blockersSemantic proximity
An inherent T cell-activating mRNA delivery platform for <i>in vivo</i> CAR T generationSemantic proximity
TREM1 <sup>+</sup> regulatory myeloid cells expand in steatohepatitis-HCC and associate with poor prognosis and therapeutic resistance to immune checkpoint blockadeSemantic proximity
Select a neighboring publication to make it the new centre.